Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3247-3257

  Kaijser, G P ^a   Keizer, H J ^b   Beijnen, J H ^c   Bult, A ^a   Underberg, W J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

2 and 3 dechloroethylifosfamide; Cancer patients; Ifosfamide; pharmacokinetics

Indexed keywords

DRUG METABOLITE; DRUG METABOLIZING ENZYME; IFOSFAMIDE;

ADULT; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INDUCTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0029838248     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Allen LM, Creaven PJ, Nolson RL: Studies on the human pharmacokinetics of isophosphamide (NSC:-109724). Cancer Treat Rep 60: 451-458, 1976.
2. Coleman RE, Harper PG, Gallagher C, Osboume R, Rankin EM, Silverstone AC, Slevin ML, Souhami RL, Toblas S, Trask GW, Willshaw E: A phase study II carcinoma of the cervix. Cancer Chemother Pharmacol 18: 189-193, 1986.
3. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH: High-dose ifosfamide with mesna uroprotection; A phase I study. J Clin Oncol 8: 170-178, 1990.
4. Gibaldi M, Perrier D: Enzyme induction. In: Pharmacokinetics. Marcel Dekker Inc. New York, USA, 2nd adition, pp 303-318.
5. Goren MP, Wright RK, Pratt CB, Pell FE: Dechloroethylation of ifosfamide and neurotoxicity. Lancet II: 1219-1220, 1986.
6. Kaijser GP, Beijnen JH, Bult A, Wiese G, De Kraker J, Underberg WJM: Gas chromatographic determination of ifosfamide in microvolumes of urine and plasma. J Chromatogr 571: 121-131, 1991.
7. Kaijser GP, Beijnen JH, Bult A, Wiese G, De Kraker J, Keizer HJ, Underberg WJM: Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine. J Chromatogr 583: 175-182, 1992.
8. Kaijser GP, Beijnen JH, Jeunink EL, Bult A, Keizer HJ, De Kraker J, Underberg WJM: The determination of chloroacetaldehyde-αmetabolite of oxazaphosphorine drugs in plasma. J Chromatogr 614: 253-259, 1992.
9. Küpker F, Boos J, Blaschke G, Jürgens H: Inhibitors of ifosfamide metabolism by human and rat liver microsomes (abstract). EORTC meeting. Rotterdam, The Netherlands, 23-26 June 1993.
10. Kurowski V, Cerny T, Küpfer A, Wagner T: Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Clin Oncol 117(Suppl IV):S148-153, 1991.
11. Leblanc GA, Waxman DJ: Mechanisms of cyclosphosphamide action on hepatic P-450 expression. Cancer Res 50: 5720-5726, 1990.
12. Lowis LD, Meanwell CA: Ifosfamide pharmacokinetics and neurotoxicity. Lancet i: 175-176, 1990.
13. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ: Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30: 725-732, 1990.
14. Lewis LD, Fitzgerald DL, Mohan P, Thatcher N, Harper PG, Rogers HJ: The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 31: 77-82, 1991.
15. Thatcher N, Wilkinson PM: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25: 139-142, 1989.
16. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49: 753-757, 1989.
17. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM: The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmac 30: 140-143, 1990.
18. Lind MJ, Roberts HL, Thatcher N, Idle JR: The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111, 1990.
19. 31P nuclear magnetic resonance spectroscopy. J Pharm Exper Ther 260: 1133-1144, 1991.
20. Mc Neil NO, Morgan LR: The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int J Clin Pharmacol Ther Tox 19: 490-493, 1981.
21. Miller LJ, Eaton VE: Ifosfamide-induced neurotoxicity: a case report and review of the literature. Ann Pharmacother 26: 183-187, 1992.
22. Misiura K, Okruszek A, Pankelwicz K, Stec WJ, Czownicki Z, Utracka B: Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26: 674-679, 1983.
23. Nelson RL, Allen LM, Creaven PJ: Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther 19: 365-370, 1975.
24. Pearcy R, Calvert R, Mehta A: Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervival carcinoma. Cancer Chemother Pharmacol 22: 353-355, 1988.
25. Piazzo E, Cattaneo MT, Varini M: Pharmacokinetic studies on lung cancer patients. Cancer 54: 1187-1192, 1984.
26. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W: Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat rep 64: 1061-1066, 1980.
27. Sladek NE, Doeden D, Powers JF, Krivit W: Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients given repeatedly high doses of cyclophosphamide in preparation for hone marrow transplantation. Cancer Treat Rep 68: 1247-1254, 1984.
28. Sladek NE: Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301-355, 1988.
29. Varini M: Ifosfamide in tumor therapy-An overview. Contr Oncol 26: 12-21, 1987.
30. Wagner JG, Christensen M, Sakmar E, Blair D, Yates JD, Willis PW, Sedman AJ, Stoll RG: Equivalence lack in digoxin plasma levels. J Am Med Assoc 224: 199-204, 1973.
31. Wagner T, Drings P: Pharmacokinetics and bioavailability of oral ifosfamide. Drug res 36: 878-880, 1986.
32. Wagner T: Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children- a comment. Cancer Chemother Pharmacol 24: S7, 1989.